Trial Profile
Feasibility Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Stage III Melanoma Patients
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 13 Dec 2023
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Acronyms OpACIN
- 24 Oct 2023 Results (n=86) assessing 4-yr event free survival rate in melanoma patients treated with ipilimumab plus nivolumab were presented at the 48th European Society for Medical Oncology Congress
- 18 Jan 2023 Results assessing survival rate in the OpACIN and OpACIN-neo trials published in the Annals of Oncology
- 13 Sep 2022 Results from three clinical studies (OpACIN, OpACIN-neo and PRADO) assessing clinical and tumor characteristics of patients with recurrence after pathologic response presented at the 47th European Society for Medical Oncology Congress